AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 4:05 PM ET Spero Therapeutics reported a net loss of $44.3 million for the third quarter of 2026 and cash of $107.9 million as of September 30, 2026. AI-generated summary · Source: company release
Nasdaq: $SPROBiopharmaceuticals

SPRO Stock Hub: Spero Therapeutics News, Operations and Capital

Spero Therapeutics has changed identity in 2026: its partnered oral antibiotic, Utebzi, reached FDA approval under GSK, while the company itself now rests on SP001, an in-licensed CD40L antibody that has yet to enter a U.S. trial. A $105 million royalty financing funded the pivot, converting future GSK payments into present cash and leaving a thin equity cushion. The hub separates partner evidence, company disclosure, accounting effects and obligations.

Last updated: November 21, 2026Financial period: Quarter and nine months ended September 30, 2026 (Form 10-Q filed November 12, 2026)Currency: U.S. dollars (thousands in filings; millions where the company rounds)
Full research report · PDF
Spero Therapeutics ($SPRO), research updated November 21, 2026
20 pages. For personal use only: redistribution prohibited.
Get the report (PDF)
Next milestone
The next formal milestone is FDA clearance of the SP001 U.S. IND, which the company has not dated; its planned Phase 2 start is Q2 2027.

Catalyst calendar.

Spero Therapeutics SPRO daily stock chart
Daily chart $SPRO. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts →

SPRO stock at a glance

Chart analysis · JC
Technical chart analysis of $SPRO with bull and bear scenarios on JC Just Charts.
Cash and cash equivalents, September 30, 2026
$107.9 million
Net loss, quarter ended September 30, 2026
$44.3 million
Acquired in-process R&D, quarter ended September 30, 2026
$35.0 million
Royalty-financing liability, total at September 30, 2026
$103.0 million
Net cash used in operations, nine months ended September 30, 2026
$32.1 million
Total stockholders' equity, September 30, 2026
$0.8 million

Where Spero Therapeutics stands now

Spero has one clinical-stage candidate and a contingent interest in a newly approved antibiotic. The nearest scientific test is regulatory rather than clinical: the company has said it plans a Phase 2 study of SP001 in IgG4-related disease, conditional on FDA clearance of a U.S. IND, and the filing itself warns that agency acceptance of China-generated data is not assured.

The financial posture is unusual. Booked cash is ample against current spending, yet nearly all of it is offset by a liability tied to future GSK payments, and book equity is close to zero. Management guides to a runway into the second half of 2029; that is a company expectation, not a contract.

Governance is turning over in parallel. The Chief Operating Officer retires at year-end, a new Chief Medical Officer and a Chief Regulatory and Quality Officer have been added, and one director was replaced in November. These indicate where the build-out sits and where execution risk concentrates.

Latest Spero Therapeutics news

Nov 12, 2026

Spero Therapeutics announces third quarter 2026 operating results and provides business update

Spero Therapeutics reported a net loss of $44.3 million for the third quarter of 2026, compared to $7.4 million for the third quarter of 2025. Cash and cash equivalents were $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029. Spero plans to initiate a Phase 2 study of SP001 in IgG4-related disease in Q2 2027.

Nov 10, 2026

Spero Therapeutics appoints William Ho, M.D., Ph.D., to its Board of Directors

Spero Therapeutics appointed William Ho, M.D., Ph.D., to its Board of Directors and Development Committee, effective as of November 10, 2026. Dr. Ho fills the vacancy created by the departure of Dr. Patrick Vink, who is stepping down after an eleven-year tenure. Dr. Ho was Chief Medical Officer of RAPT Therapeutics from 2015 to December 2025 and has more than 20 years of clinical development experience.

Nov 4, 2026

Spero Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4)

The Compensation Committee of Spero Therapeutics' Board of Directors approved a grant made on November 2, 2026, of 217,000 restricted stock unit awards and 434,000 stock options to a new employee under the 2019 Inducement Equity Incentive Plan. The awards were granted as an inducement material to the new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest as to 25% on the first anniversary of the vesting start date, with the remainder vesting in 36 equal monthly installments thereafter. The RSUs vest in four equal annual installments beginning on the first anniversary of the vesting start date.

Nov 2, 2026

Spero Therapeutics to present at investor conferences in November

Spero Therapeutics announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA, on Tuesday, November 10. The company will also participate in the Jefferies Global Healthcare Conference in London, UK, on November 18-19, where its leadership team will be available for investor meetings. Meeting requests should be made through each conference's institutional contact.

Oct 27, 2026

Form 8-K: retiring Chief Operating Officer to advise on the transition until about February 28, 2027

A Form 8-K filed on October 27, 2026 (Item 5.02) states that the Chief Operating Officer will retire effective December 31, 2026, after 11 years with the company. Spero expects to enter into a consulting arrangement with the executive on or about that date, under which advisory services supporting the transition would run until approximately February 28, 2027, unless either party ends the arrangement earlier on fifteen days’ written notice. The executive would be paid an hourly rate. Form 8-K

Oct 26, 2026

New regulatory and corporate development leaders; Chief Operating Officer to retire

Spero appointed a Chief Regulatory and Quality Officer, who will lead global regulatory strategy, quality and pharmacovigilance, including engagement with health authorities on SP001 in Ig G4-related disease and potential further indications, and a Senior Vice President, Corporate Development, who will lead investor relations strategy and business development, including opportunities to expand the immunology pipeline. The new regulatory chief most recently led regulatory sciences at Vir Biotechnology; the new corporate development head most recently led strategy and business development at Fulcrum Therapeutics, after years in biotechnology equity research. The Chief Operating Officer, with the company for 11 years and central to the Utebzi program licensed to GSK, will retire effective December 31, 2026; the role’s responsibilities will pass to other members of the executive team. The announcement contained no new clinical data or guidance.

Catalyst calendar

  • June 17, 2026: FDA approved Utebzi for complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms in adults with limited or no alternative oral treatment options, per the FDA approval record.
  • July 8, 2026: Innovent license agreement for SP001 and entry into the HCRx royalty-financing transaction, per the Form 10-Q. The earnings release describes the financing as closed in July 2026.
  • September 30, 2026: balance sheet date reporting $107.9 million of cash, per the earnings release.
  • October 26, 2026: retirement of the Chief Operating Officer announced, effective December 31, 2026, per the Form 8-K.
  • November 6, 2026: share count reference date of 58,264,577 shares, per the Form 10-Q.
  • November 10, 2026: director change effective, per the Form 8-K.
  • November 12, 2026: third-quarter results announced and Form 10-Q filed, per the Form 8-K and the earnings release.
  • December 31, 2026: effective date of the COO’s retirement; advisory period runs to about February 28, 2027, per the Form 8-K.
  • Q2 2027: company-planned start of the SP001 Phase 2 study in IgG4-RD, subject to FDA IND clearance, per the earnings release.
  • Date not disclosed: U.S. IND clearance for SP001.

Spero Therapeutics deep dive: the full analysis

The Merlintrader Research Library collects our dated biopharmaceuticals stock research reports.

01 Evidence that would change the thesis

The thesis here is that Spero is a single-program immunology developer financed by monetizing a partner’s antibiotic, with value contingent on regulatory acceptance of SP001 and on the pace of cash use. Three families of evidence would move that view.

Constructive scenario. The U.S. IND is cleared without a request for substantial additional data, and the company discloses the Phase 2 design, sites and endpoints consistent with its Q2 2027 plan. Subsequent filings would ideally show quarterly cash use close to the nine-month 2026 pattern rather than a step up, which would support the runway statement in the earnings release. A disclosed Utebzi launch with reported GSK sales would begin the royalty clock described in chapter 9, though the 35% residual interest would only matter after noteholders are repaid.

Cautious scenario. The FDA signals that the China-generated Phase 1b data in Sjögren’s disease do not suffice for a U.S. IND, a risk the company itself flags in its risk factors. That would add a study before Phase 2 and push spending ahead of the plan. Likewise, if Utebzi sales ramp slowly, royalties may take longer to retire the notes, and the company’s economic interest could stay deferred well beyond the runway horizon.

Observable falsifiers. The following would contradict the working thesis rather than merely stress it:

ObservableWhat it would contradictWhere to check
IND clearance requiring new non-clinical or clinical workPhase 2 timing in Q2 2027Company releases and 10-Q
Quarterly operating cash use well above the nine-month averageRunway into second half of 2029Next 10-Q cash flow statement
Additional equity issuance or a new financingStatement that the royalty financing is non-dilutive and sufficient8-K and 10-Q equity statement
Termination or amendment of the GSK or Innovent agreementsPartner-dependence structure8-K Item 1.01 or 1.02
Safety signal in any SP001 studyMechanistic design claim about platelet activationClinical disclosures

Because current book equity is $0.8 million, small accounting changes matter more than they would for a better-capitalized peer. Readers can assess that independently using the balance sheet.

02 From antibiotic developer to immunology company

Spero’s 10-Q now describes a clinical-stage company “focused on advancing next generation medicines for patients with immune-mediated diseases,” per Note 1 of the Form 10-Q. That wording would have been unrecognizable to anyone reading the company’s earlier filings, which centered on antibacterial resistance. Two earlier programs, SPR206 and SPR720, are described in the same filing as terminated, leaving SP001 as the only asset in clinical development.

The restructuring of purpose is more consequential than the in-licensing alone. A company whose institutional expertise lay in antibacterial development, regulatory strategy for infection indications and partnership management with a large pharmaceutical licensee is now building capabilities in antibody development for rare, chronic immune disease. The company’s own risk factors concede this, calling the move a “strategic pivot” into indications where it has “relevant but limited prior experience.”

The hiring pattern reads as a response. Per the earnings release, a new Chief Medical Officer arrived in July 2026, a Chief Regulatory and Quality Officer was appointed to lead regulatory strategy, quality and pharmacovigilance, and a physician-scientist with antibody development experience joined the board. The Chief Operating Officer, an eleven-year veteran, retires on December 31, 2026, per the Form 8-K, with a consulting transition to about February 28, 2027. Institutional memory of the antibiotic era is leaving as new capabilities arrive.

Spero reports one operating segment, is a non-accelerated filer and a smaller reporting company, and has no preferred stock outstanding. Stockholders approved the amendment increasing authorized common shares from 120 million to 240 million, and Spero filed it in Delaware on June 23, 2026. The November 6 share count was 58,264,577. The Form 10-Q distinguishes this increase in issuance capacity from shares outstanding.

A useful way to frame the company is by what it owns, what it licenses and what it owes:

PositionAsset or claimCounterpartyStatus
Holds exclusive license ex-Greater ChinaSP001Innovent (retains Greater China)In-licensed July 8, 2026
Holds contingent payment rightsUtebzi milestones and royaltiesGSKFDA approved June 2026; eligible GSK proceeds service the notes before Spero receives a residual share
Owes future GSK-derived paymentsNotesHCRxNon-recourse; entered July 8, 2026 and closed July 2026

Each row is analyzed in its own chapter: the licensing terms in chapter 3, the financing in chapter 9, and the antibiotic in chapter 12.

03 The Innovent license: what Spero acquired and where its rights stop

On July 8, 2026, Spero entered an agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc., described in Note 1 of the Form 10-Q. The grant is a sublicensable license under patent rights and know-how to research, develop, manufacture and commercialize SP001 plus certain backup and derivative monoclonal antibodies targeting CD40L, worldwide except Mainland China, Hong Kong, Macau and Taiwan.

Three features of the grant deserve separate attention. First, the exclusivity runs “even as to Innovent and its affiliates,” but with a carve-out: Innovent keeps the right to conduct certain research, non-clinical development and manufacturing activities. A licensee relying on a licensor for some manufacturing and non-clinical work has a dependency that does not appear in the balance sheet. Second, the license covers backup and derivative antibodies, which gives optionality if SP001 fails but also expands the diligence surface. Third, Greater China remains with Innovent, so any global development narrative is geographically partial.

The Form 10-Q states that Spero paid the $35.0 million upfront amount in August 2026 and recognized it as acquired in-process research and development in the third quarter. The earnings release groups the charge with ordinary R&D. The $35.0 million payment and $3.196 million of ordinary R&D total $38.196 million, or $38.2 million rounded.

The Form 10-Q also discloses up to approximately $1.05 billion in cumulative development, regulatory and commercial milestones. These conditional payments were unaccrued at September 30 because they were not yet probable. Innovent is eligible for tiered royalties on annual net sales from a high-single-digit percentage to the mid-teens, subject to contractual reductions. The agreement also contemplates ancillary agreements, including clinical supply. The milestone ceiling measures potential exposure over development and commercialization. Payment timing depends on the applicable milestones being achieved.

A practical test of the license’s value sits outside the accounting: whether the FDA accepts the Innovent-generated data package as support for an IND. The risk factors warn that acceptance of data from trials conducted outside the United States, including China, “may be subject to certain conditions, or such data may not be accepted at all,” and they cite a May 2026 non-binding draft House Appropriations Committee report that would restrict FDA consideration of clinical data from sites in certain countries. That draft is not law. It matters because it is a policy variable outside company control that bears directly on the asset’s acquired data.

04 Quarterly P&L: how to read a $44.3 million loss

The quarter ended September 30, 2026 produced a net loss of $44,278 thousand against $7,382 thousand a year earlier, per the statements of operations. A $36.9 million deterioration looks alarming until the components are separated.

Line, three months ended September 30 (USD thousands)20262025
Total revenues05,442
Acquired in-process R&D35,0000
Research and development3,1968,597
General and administrative3,7174,174
Impairment charges0587
Loss from operations(41,913)(7,916)
Interest income912532
Interest expense, royalty financing(3,278)0
Net loss(44,278)(7,382)

Source: Form 10-Q for the quarter ended September 30, 2026, filed November 12, 2026.

Three effects drive the change. The one-time $35.0 million licensing charge explains most of the gap. Revenue vanished: the prior-year quarter included $2,394 thousand of grant revenue and $3,048 thousand of related-party collaboration revenue, none of which recurred. And a new financing cost of $3,278 thousand appears below the operating line.

Excluding the acquired in-process charge, operating expense was $6,913 thousand in the quarter versus $13,358 thousand a year earlier. That is a calculation from the filing’s line items, not a company-reported measure. It shows a smaller organization: ordinary R&D fell by $5,401 thousand year over year, consistent with the wind-down of the antibiotic programs, and general and administrative fell by $457 thousand, which the release attributes primarily to decreased personnel costs per the earnings release.

Net loss per share was $0.76 on 58,229,386 weighted shares, versus $0.13 on 56,280,844 a year earlier. The per-share figure inherits all the distortions above, so it is not a clean trend indicator.

The more important read is forward-looking. The quarterly R&D run-rate of $3.2 million reflects a company between programs. Spending on a Phase 2 study, manufacturing for clinical supply, and a larger regulatory and quality function should raise it. The nine-month figures in chapter 5 show the same pattern at a longer horizon. Interest expense on the royalty financing, which is non-cash in the first period per the cash flow statement, is a recurring accounting charge that will persist while the liability is outstanding and does not map to current cash outlays.

05 Nine-month view and the disappearance of collaboration revenue

The nine-month period gives a wider baseline than the single quarter, and it exposes how much of 2025’s revenue base has rolled off. Revenue for the nine months ended September 30, 2026 was $258 thousand versus $25,505 thousand in the prior-year period, per the statements of operations.

Nine months ended September 30 (USD thousands)20262025
Grant revenue05,544
Collaboration revenue, related party25819,949
Collaboration revenue, other012
Total revenues25825,505
Acquired in-process R&D35,0000
Research and development9,53932,875
General and administrative15,09616,876
Total operating expenses59,63550,596
Net loss(61,033)(22,948)
Net loss per share$(1.06)$(0.41)

Source: Form 10-Q, nine months ended September 30, 2026.

The pattern is that revenue and R&D fell together. In 2025 the company was recognizing deferred revenue from its GSK arrangement while spending on the Phase 3 program; in 2026 both effects are largely gone. Ordinary R&D dropped by $23,336 thousand, and revenue by $25,247 thousand. Revenue recognition here is non-cash in character: the 2026 cash flow statement shows a $258 thousand reduction in related-party deferred revenue, matching the revenue recognized, so there was no fresh cash inflow behind it.

General and administrative expense averaged about $5.0 million per quarter through September, compared with $3.717 million in Q3. The nine-month and latest-quarter figures give different baselines for future spending.

A simple illustration, labeled as arithmetic and not a company-reported figure: removing the $35.0 million acquired in-process charge from the nine-month net loss leaves $26,033 thousand. That is useful for comparing underlying spending with the prior year’s $22,948 thousand loss, but note that the prior year’s loss was cushioned by $25.5 million of revenue that is no longer present. Underlying expense, not underlying loss, is therefore the cleaner comparator: operating expense excluding the acquired charge was $24,635 thousand in 2026 versus $50,596 thousand in 2025.

Interest income was $1,625 thousand for the nine months versus $2,136 thousand a year earlier, despite higher cash late in the period. Cash at December 31, 2025 was $40,265 thousand, and the larger balance resulting from the July 2026 financing has had only one quarter to earn income. The share count rose from 56,414,657 at December 31, 2025 to 58,237,077 at September 30, 2026, entirely from restricted stock unit vesting of 1,822,420 shares per the equity statement, a modest dilution source examined in chapter 10.

06 Cash, runway language and what is and is not guaranteed

Cash and cash equivalents were $107,928 thousand at September 30, 2026, compared with $40,265 thousand at December 31, 2025, per the balance sheet. The company states in its earnings release that cash is “expected to fund operations into the second half of 2029.” Several distinctions apply to that sentence.

ItemCategoryAmount or statement
Cash and cash equivalents, September 30, 2026Booked cash$107.9 million
Runway into second half of 2029Company forward expectationNot a contract or audited figure
Milestones and royalties from GSKContingent, partner-dependentLargely assigned to noteholders
Payments to HCRxNon-recourse; payable from GSK proceeds assigned to HCRxDescribed as non-recourse; the 10-Q describes HCRx as receiving a portion of future GSK proceeds

The runway statement is a management estimate. It is built on assumptions about clinical timing, manufacturing costs and regulatory interactions, each of which the company’s risk factors describe as uncertain. The release does not disclose planned quarterly spending, the size of the Phase 2 study, or the headcount plan, so the denominator of the runway claim cannot be independently reconstructed. A reader can test the claim only against observed cash use over time.

Observed cash use gives a baseline. Net cash used in operating activities was $32,098 thousand for the nine months ended September 30, 2026, versus $4,273 thousand in 2025, per the cash flow statement. The comparison flatters 2025 because that year’s operating cash was supported by a $48,523 thousand reduction in related-party receivables from GSK, whereas in 2026 a $25,359 thousand collection of the remaining receivable offset part of the burn. The receivable is now zero on the balance sheet. Future operating cash use therefore lacks the cushion of collections, which is why the 2026 figure is a better guide to the cash cost of operating the company than the 2025 one.

Simple arithmetic, not a company projection: nine-month operating cash use of $32.1 million included collections of $25.4 million, so operating cash use before that collection was larger. The cash flow statement shows the nine-month net loss of $61.0 million with no separate add-back for the $35.0 million acquired in-process charge, which indicates that the payment is included in operating cash use. That reading is an inference from the totals rather than a line-by-line company statement.

Net cash provided by financing activities was $99,761 thousand, composed of $103,175 thousand of proceeds, reported net, less $3,414 thousand of transaction costs. Cash rose $67,663 thousand. The release describes the $105 million headline; the net cash figure is lower by transaction costs, a difference worth tracking when comparing headlines to balance sheets.

07 Operating cash flow: what moved and what did not

The cash flow statement is presented for nine months only, so quarterly operating cash cannot be derived from the filing. The nine-month detail still shows the quality of the burn.

Nine months ended September 30 (USD thousands)20262025
Net loss(61,033)(22,948)
Stock-based compensation2,7913,318
Non-cash interest, royalty financing3,2780
Collaboration receivable, related party25,35948,523
Deferred revenue, related party(258)(19,949)
Accounts payable(282)(5,911)
Accrued expenses and other current liabilities(1,539)(9,915)
Net cash used in operating activities(32,098)(4,273)

Source: Form 10-Q, condensed consolidated statements of cash flows, nine months ended September 30, 2026 and 2025.

The largest bridge item between the $61.033 million net loss and the $32.098 million of operating cash used was collection of $25.359 million of previously recognized GSK receivables. That collection was about 42% of the net loss and accounted for most of the $28.935 million difference between the two measures. Noncash stock compensation, lease expense and accrued royalty-financing interest added back a separate $6.753 million. Changes in payables and accrued expenses used $1.821 million. These amounts come from the cash-flow statement in the Form 10-Q.

For a reader building a forward view, the fair statement is that 2026’s operating cash use is a mix of a one-time $35.0 million licensing outlay, a one-time collection inflow, and a thin base of ordinary spending. None of those three components is a reliable proxy for 2027 operations, which will carry clinical trial costs absent from 2026. The company’s runway claim implicitly assumes that spending ramps in a manageable way; the first evidence for or against that assumption will come from the quarter in which Phase 2 start-up costs begin.

The $3.278 million royalty-financing interest was a noncash charge in the nine-month cash-flow statement. Under the agreement, available GSK proceeds service the notes and interest not covered by available proceeds is added to the balance. Default rights and the limited guarantee are described in chapter 9.

Finally, the equity statement shows stock-based compensation of $2,791 thousand for nine months, with $855 thousand in the third quarter, per the statement of stockholders’ equity. Stock compensation is the one recurring non-cash expense that produces share issuance, through restricted stock unit vesting.

08 Utebzi: separating regulatory, clinical and commercial evidence

The FDA approval record shows that the agency approved Utebzi (tebipenem pivoxil) on June 17, 2026 to treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms in adults with limited or no alternative oral treatment options.

The clinical record sits at three tiers. Company and partner disclosure: the 10-Q states that the pivotal Phase 3 PIVOT-PO trial met its primary endpoint and stopped early for efficacy in May 2025, with GSK resubmitting the NDA in December 2025. Peer-reviewed trial-derived analysis: Bhavnani and colleagues, in Open Forum Infectious Diseases, 2024, pooled data from 366 tebipenem-treated and 378 ertapenem-treated patients in a global Phase 3 study and found that urinary tract anatomical and functional disorders predicted nonresponse, while baseline fluoroquinolone susceptibility and creatinine clearance above 50 mL/min predicted better response. Independent review: Alkhanafsa and colleagues, in Infection, 2026, a narrative review through August 12, 2026, concluded that ADAPT-PO and PIVOT-PO showed noninferiority of complete oral tebipenem regimens against intravenous comparators, that activity against many ESBL- and AmpC-producing Enterobacterales is retained but not against major carbapenemases, and that no trial randomized clinically improving patients after initial intravenous therapy.

That last point is a limit on what can be said about use patterns. The trials tested complete oral regimens against intravenous comparators, not a sequenced intravenous-to-oral strategy. The review also names open questions: limited bacteremia data, adherence on a dosing schedule it describes as every six hours, optimal duration, cost-effectiveness, microbiome effects and resistance selection.

GSK owns the NDA and IND and is responsible for commercialization in the licensed territories. The Form 10-Q describes launch and sales milestones and royalties on annual net sales. The contractual royalty tiers are 1% on sales up to $750 million, a high-single-digit rate on sales above $750 million through $1 billion and a low-double-digit rate on sales above $1 billion. Payment to Spero is also subject to the royalty-financing terms in chapter 9.

Commercial sales will determine how quickly eligible proceeds retire the HCRx notes and when Spero can begin receiving its residual share.

A final distinction: the Infection review is a secondary synthesis, not a prospective trial. It informs context on use limits but cannot substitute for partner sales disclosure or label text. Readers should treat the Bhavnani analysis as a post hoc multivariable analysis of trial data, which describes predictors rather than treatment effects.

09 The HCRx financing: how a royalty sale shows up in the accounts

The most important financial instrument in the filing is the milestone and royalty financing closed in July 2026. Per the earnings release, Spero closed a $105 million non-recourse, non-dilutive financing with affiliates of HealthCare Royalty Partners, a business of KKR, referred to as HCRx, in exchange for a portion of anticipated Utebzi payments owed by GSK to Spero. The 10-Q adds that Spero’s receipt of royalty and milestone revenue from GSK is limited to 35% of GSK proceeds arising after the notes are paid in full.

The accounting presents this as debt-like. The balance sheet carries the liability in two lines.

Liability related to sale of future milestones and royalties, September 30, 2026 (USD thousands)Amount
Current portion50,756
Non-current portion52,283
Total103,039

Source: Form 10-Q, condensed consolidated balance sheet.

Note 10 of the Form 10-Q reconciles the September 30 carrying amount (USD thousands): $106,575 of face principal less $3,150 of initial debt discount and $3,664 of issuance costs recognized as discount, plus $3,278 of noncash interest, equals $103,039. The statement of cash flows measures cash activity separately: $103,175 of proceeds reported net, less $3,414 of issuance costs paid, gave $99,761 of net financing cash inflow.

The $50.756 million current portion reflects management estimates for the amount and timing of expected GSK proceeds. The notes accrue interest at 10% annually and have a nine-year maturity. Interest that available proceeds do not cover is capitalized. The Form 10-Q describes acceleration and collateral remedies after default and a limited guarantee by Spero that applies in specified circumstances.

Eligible GSK milestone and royalty proceeds go toward principal and interest until the notes are paid in full. After full repayment, Spero is entitled to 35% of GSK proceeds. The pace of repayment depends on GSK commercialization and satisfaction of the payment thresholds in the underlying license.

This is also why the label “non-dilutive” should be read narrowly: it describes no share issuance for this transaction, not the absence of a claim on future economics.

10 Balance sheet and capital structure: a thin equity cushion

On September 30, 2026, total assets were $110,026 thousand and total liabilities $109,245 thousand, leaving stockholders’ equity of $781 thousand, per the balance sheet. At December 31, 2025, equity was $59,021 thousand. Equity fell by $58,240 thousand over nine months, tracking the $61,033 thousand net loss offset by $2,791 thousand of stock compensation and $2 thousand from restricted stock unit vesting.

Selected balances (USD thousands)September 30, 2026December 31, 2025
Cash and cash equivalents107,92840,265
Total current assets109,22867,286
Total current liabilities56,9628,868
Royalty-financing liability, non-current52,2830
Total liabilities109,2459,898
Total stockholders’ equity78159,021

Source: Form 10-Q, condensed consolidated balance sheets.

The near-zero equity is an accounting outcome with specific causes. The royalty financing was booked as a liability rather than as income, so $105 million of cash raised produced no equity credit, while the $35.0 million licensing charge and operating costs reduced equity. Accumulated deficit reached $512,099 thousand against additional paid-in capital of $512,822 thousand.

Spero is listed on the Nasdaq Global Select Market, according to the 10-Q cover page. Book equity of $0.8 million leaves a small accounting buffer against future losses.

Shares outstanding rose about 3.2%, from 56,414,657 at year-end to 58,237,077 at September 30, because of restricted stock unit vesting. The Form 10-Q reports 58,264,577 shares on November 6. Under the August 28 at-the-market agreement with Jefferies, Spero can sell up to $100 million gross of common stock under its $300 million shelf, which became effective on September 10. The authorized share increase and the sales agreement provide capacity for future issuance. They do not show proceeds already received. Preferred authorization is 10 million shares, with none outstanding.

The capital structure thus has three layers: a large non-recourse liability serviced by third-party payments, a small equity cushion, and no outstanding preferred stock. Cash of $107.9 million is nearly equal to the royalty-financing liability of $103.0 million, but the two are not netted for economic purposes. The liability is repaid from GSK flows, whereas the cash is available for operations. A fair reading is that the company has used future partner revenue to fund an immunology pipeline, trading a long-dated asset for present flexibility.

11 SP001: the science case, the evidence gap and what is a design claim

Spero describes SP001 as an investigational monoclonal antibody that targets CD40 ligand, an immune signaling protein, in the Form 10-Q. The planned IgG4-RD study will assess the investigational treatment in the target patient population.

The Form 10-Q reports that Innovent completed early studies in healthy volunteers and a Phase 1b study in primary Sjögren’s disease in China. Innovent presented the Phase 1b findings at EULAR 2026. Spero plans to start a separate Phase 2 study in IgG4-related disease in Q2 2027, subject to FDA clearance of its IND.

The evidence ladder for SP001 should be stated plainly:

EvidenceReported statusOpen question
MechanismInvestigational CD40L antibodyClinical benefit and safety in IgG4-RD
Early human dataInnovent Phase 1 and 1b completed, per company releaseNumerical results in the company’s filings or release
Target indication dataNoneAny IgG4-RD patient data
U.S. regulatory standingIND plannedIND clearance

The inferential step from Sjögren’s disease data to IgG4-RD is a leap that the company’s risk factors acknowledge in part, noting that the planned Phase 2 is “based in part on data generated by Innovent in its Phase 1b study conducted in China in patients with SjD.” The two diseases share an immune-mediated, tissue-infiltrating character but differ in clinical course and organ involvement; the company describes IgG4-RD as a rare, chronic, fibroinflammatory condition that can affect the pancreas, kidneys, lungs, salivary and lacrimal glands and lymph nodes, per the release.

The class history is relevant context without being evidence for SP001. The company’s own reference to “platelet activation concerns associated with earlier anti-CD40L antibodies” is an acknowledgment that the target has a safety history. Whether a modified Fc design resolves it can only be shown by prospective safety data in patients, which for Spero does not yet exist. The filing’s standard warnings about adverse events, interim data changing and the failure of early-stage results to predict later trials all apply with particular force to a program with no company-sponsored human data.

12 Antibiotic literature: what peer-reviewed work says, and what it cannot say about Spero's finances

The Utebzi literature describes patient populations, treatment comparisons and the remaining clinical questions relevant to commercial use.

The Lancet Microbe trial by Sewunet and colleagues, 2024, is a Phase 1 randomized open-label study in healthy adults at Karolinska University Hospital comparing oral tebipenem pivoxil hydrobromide with amoxicillin-clavulanic acid, with ten days of treatment and follow-up to day 180, measuring gut microbiome diversity and selected taxa by sequencing and quantitative culture. No finding from that study is reported here. Its relevance is that the Infection review names microbiome effects as an open question.

Melnick and colleagues, Antimicrobial Agents and Chemotherapy, 2023, analyzed a completed trial comparing oral tebipenem with intravenous ertapenem and reported that ertapenem’s prolonged urinary clearance and dwell time were associated with a temporal difference in the return of bacteria to bladder urine after treatment, which could confound efficacy assessment. For readers, this is a methodological caution on interpreting microbiological endpoints in cUTI trials, not a verdict on either drug.

Comparator and adjacent evidence, kept distinct from Utebzi, includes Seo and colleagues, Clinical Infectious Diseases, 2026, a randomized noninferiority trial of oral fosfomycin versus continued intravenous therapy in 299 randomized adults with ESBL-producing Enterobacterales complicated UTI who had improved after 3 to 7 days of intravenous antibiotics, reporting clinical cure of 92.8% versus 95.2% and concluding noninferiority. That trial tested a different oral drug in a step-down design, which is the design the Utebzi trials did not test, per the Alkhanafsa review. It illustrates the competitive and evidentiary context for oral transition strategies, but it cannot be read across to tebipenem.

Yildiz Dikmen and colleagues, Diagnostic Microbiology and Infectious Disease, 2026, found urinary NGAL added no diagnostic value beyond conventional markers in 259 adults, with CRP and white cell count higher in complicated UTI. Lashkar and Nahata’s Antibiotics review, 2026 addresses neonates and young infants, a population outside the approved adult indication. A 2026 Cureus case report on Staphylococcus lugdunensis spinal-joint infection is unrelated to urinary infection or to Utebzi and is not used here.

The disciplined takeaway is separation of purposes. These papers describe the clinical landscape in which an oral carbapenem may be used. They do not describe Spero’s cash, and nothing in them supports a statement about royalty size or timing. For financial interpretation, the filing disclosures govern; for scientific context, these sources frame uncertainty about use and comparators.

13 Governance and people: continuity risk during a pivot

Pivot companies are judged on whether leadership capacity matches the new program. Spero’s Form 8-K and release disclosures show deliberate recruiting alongside departures.

DateEventSource
July 2026Chief Medical Officer appointed to lead clinical development strategyEarnings release
Date not stated (described as recent)Chief Regulatory and Quality Officer appointed, covering regulatory strategy, quality and pharmacovigilanceEarnings release
October 26, 2026COO retirement announced, effective December 31, 2026Form 8-K
November 9–10, 2026Class II director resignation notice (November 9) and appointment of a new Class II director; both effective November 10Form 8-K

Source: Spero Form 8-K filings dated October 27 and November 10, 2026 and earnings release dated November 12, 2026.

Several points follow. The director resignation was not the result of any dispute or disagreement, per the 8-K. The incoming director, according to the filing, served as Chief Medical Officer of RAPT Therapeutics from 2015 to December 2025 and most recently led the U.S. and ex-China development strategy and initiation of clinical development for an in-licensed anti-IgE antibody there, a profile relevant to licensing-led antibody development. His compensation disclosed in the filing is a $40,000 annual cash retainer, $5,000 for the Development Committee, and an option over 100,000 shares vesting monthly over one year. The option grant is for 100,000 shares, small relative to roughly 58 million shares outstanding.

The departing COO’s consulting arrangement is expected to run to approximately February 28, 2027, at an hourly rate, terminable by either party on fifteen days’ notice. The Form 8-K states the company expects to enter into the arrangement on or about the retirement date.

The same executive holds the chief executive and chief financial officer roles. Concentrating both functions in one officer can make management succession more consequential during the pivot. The roles are reported in the Form 10-Q.

Hiring in regulatory, quality and pharmacovigilance is the most informative signal. Those are the functions that determine whether an IND is accepted and whether a trial can be run to inspection standards. Their presence addresses the single largest near-term uncertainty, though presence is not performance. The company’s forward-looking statements cite retention and hiring of key professionals as a risk. Observable tests include whether further executive appointments are announced, whether cash compensation or equity grants rise materially, and whether the IND timeline stays intact.

14 Risk register: the company's own warnings, ranked by what is testable

The 10-Q’s risk factors are long; the useful exercise is to rank them by whether a reader can independently observe their resolution.

RiskNatureTestable by
Dependence on a single clinical-stage programConcentrationAny SP001 safety, regulatory or enrollment event
FDA acceptance of non-U.S. dataRegulatory, policyIND outcome; any change in FDA data policy
Utebzi value depends on GSK commercializationPartnerGSK launch and sales disclosure
Third-party manufacturing relianceSupplyClinical supply disclosure and any delay
Obligations under in-license agreementsContractualAmendments, notices or disputes in filings
Financing needs beyond current cashCapitalFuture cash use against the 2029 guidance
Share price volatilityMarketChanges in trading liquidity or volatility

The company’s own risk factor summary also lists competition, safety and market-acceptance risks.

Source: Form 10-Q, risk factor summary and Part II Item 1A.

The first two deserve the most weight because they are binary and near-term. The 10-Q states that the FDA “will generally not approve the application on the basis of foreign data alone” unless conditions are met, and that data from a study not conducted under an IND will generally not be accepted unless Good Clinical Practice compliance is shown and, where needed, validated by inspection. The May 2026 draft House committee report cited in the filing is non-binding but signals a policy direction; whether it becomes binding is a variable outside the company’s control.

GSK controls Utebzi commercialization in the licensed territories. Slow uptake could defer the date when Spero receives residual GSK proceeds. Eligible GSK payments service the financing in the ordinary course, subject to the default and limited guarantee provisions in chapter 9.

Spero has historically relied on third parties for clinical supply. The Innovent license preserves certain manufacturing rights for Innovent and contemplates an ancillary clinical supply agreement. Supply readiness remains relevant to the planned 2027 trial. The terms are summarized in the Form 10-Q.

Finally, interim data caution applies to any future disclosure. The filing warns that preliminary or interim analyses may change as more patient data arrive and are subject to audit and verification. This is generic, but it is particularly relevant to a company whose first disclosed results will probably come from an early-stage trial in a rare disease with small patient numbers, where single patients can move percentages materially.

15 Peer and sector context: where Spero sits and what comparisons are fair

Spero has two distinct economic exposures. Its Utebzi interest depends on a partner’s commercialization and the royalty financing, while the SP001 program depends on clinical progress and Spero’s ability to fund development. The two exposures call for different comparisons.

The Infection review discusses oral tebipenem as a culture-directed option for selected adults. GSK commercialization and the timing of eligible payments determine Spero’s remaining economic interest.

Within immunology antibodies, the filing’s own risk discussion points to FDA conditions on foreign data and a draft appropriations report that bears on U.S. entry for China-generated data. One disclosed comparison from the filings: the incoming director, per the Form 8-K, led the U.S. and ex-China development strategy for an in-licensed anti-IgE antibody at RAPT Therapeutics, and the 8-K states the program contributed to GSK’s $2.2 billion acquisition of RAPT, finalized in March 2026. That is a disclosed biographical fact about a director’s prior employer, not a forecast for Spero, and no inference about Spero’s outcome should be drawn from it.

Spero raised capital without issuing shares by financing future GSK milestones and royalties. Available eligible payments ordinarily service the notes. The collateral and limited-guarantee terms in chapter 9 are relevant to the company’s exposure under the arrangement.

Spero is targeting the second quarter of 2027 for Phase 2, conditional on FDA clearance of its investigational new drug application.

16 A disciplined monitoring framework: ten observables and where they appear

Spero’s equity story rests on a small number of verifiable events. Upcoming filings and company updates can clarify clinical milestones, royalty financing and cash.

#ObservableConfirmed baselineWhere it appearsWhat it would show
1SP001 U.S. IND clearancePlanned; not yet dated by the companyCompany release and next Form 10-QWhether the Innovent data package suffices for U.S. entry
2Phase 2 start in IgG4-RDCompany plan: Q2 2027, subject to IND clearanceEarnings releaseWhether the stated timeline holds
3Operating cash use$32.1 million for the nine months ended September 30, 2026Next 10-Q cash flow statementWhether burn steps up as Phase 2 preparation begins
4Cash balance$107.9 million at September 30, 2026Balance sheetConsistency with the second-half-2029 runway statement
5Royalty-financing liability$103.0 million total, of which $50.8 million is classified currentBalance sheet and Note 10Pace of repayment from GSK proceeds
6Utebzi commercial disclosureFDA approval announced June 17, 2026; GSK commercial sales are the next measureGSK and Spero disclosuresWhen royalty accrual could begin
7Share count58,264,577 at November 6, 202610-Q cover pageWhether issuance beyond vesting appears
8Stockholders’ equity$0.8 million at September 30, 2026Balance sheetFurther erosion from losses
9Executive and board changesCOO retires December 31, 2026; director change effective November 10, 2026Form 8-K filingsWhether leadership capacity matches the pivot
10Partner agreement statusInnovent license and GSK arrangement in force8-K Items 1.01 and 1.02Any termination or amendment

Three of these observables are linked. IND clearance (1) gates the Phase 2 start (2), and the Phase 2 start is what would move cash use (3) away from the nine-month pattern. A reader who sees the first domino fall in either direction can reassess the other two without waiting for later filings.

Observables 4, 5 and 8 belong together because they describe the same balance sheet from different angles. Cash of $107.9 million and a royalty-financing liability of $103.0 million look nearly offsetting, but the liability is serviced from GSK payments in the ordinary course, per the 10-Q. Equity of $0.8 million is the residue of that structure plus the $35.0 million acquired in-process charge and operating losses. Each quarter should be read for all three lines together.

Future GSK commercial disclosures can help show how quickly eligible payments may retire the HCRx notes. The first milestone or royalty receipt by the noteholders and the eventual beginning of Spero’s residual share are distinct events.

Observable 9 is directional rather than binary. The Form 8-K on the director change reports no disagreement, and the COO consulting arrangement runs to about February 28, 2027. Additional appointments in regulatory, quality or clinical operations would be consistent with the build-out already disclosed.

The next periodic filing will update cash and spending, while company and regulatory announcements can establish whether the SP001 development schedule remains on track.

Merlintrader Health Score · $SPRO

3.00 out of 5
Balance sheet and runway · 30% 3.00

Balance sheet and runway: $107.9 million of cash against $32.1 million of nine-month operating cash use, with management guiding to the second half of 2029, but book equity is only $0.8 million and a $103.0 million non-recourse royalty liability sits alongside the cash, per the balance sheet.

Catalyst · 30% 3.00

Catalyst: Utebzi approval on June 17, 2026 is settled, but the SP001 U.S. IND is undated, the Phase 2 start is planned only for Q2 2027, and the company reports no clinical data of its own, per the earnings release.

Dilution · 20% 3.00

Dilution: Restricted stock unit vesting raised outstanding shares about 3.2% over nine months. The HCRx transaction issued no shares. The increase to 240 million authorized shares and $100 million Jefferies ATM provide capacity for future issuance, per the Form 10-Q.

Liquidity · 10% 3.00

Liquidity: Spero trades on the Nasdaq Global Select Market, according to the 10-Q cover. A listing supports access to buyers, while concentrated catalyst dates can affect the ease of trading.

Execution · 10% 3.00

Execution: New clinical and regulatory leaders joined, but the COO retires December 31, 2026, one officer serves as both CEO and CFO, and the company describes its experience in the new indications as “relevant but limited,” per the Form 8-K and Form 10-Q.

Assessed November 21, 2026. Merlintrader calculation: 3.00 × 30% + 3.00 × 30% + 3.00 × 20% + 3.00 × 10% + 3.00 × 10% = 3.00 out of 5.

Red flags to track

  • SP001 is the only product candidate in clinical development, so any safety, regulatory or enrollment setback affects the whole pipeline, per the Form 10-Q.
  • The U.S. IND for SP001 has not been dated by the company, and the risk factors state that FDA acceptance of China-generated data may be conditional or may not occur.
  • Stockholders’ equity was $0.8 million at September 30, 2026, down from $59.0 million at December 31, 2025, leaving little accounting cushion against further losses.
  • The $103.0 million royalty-financing liability includes $50.8 million classified as current based on expected GSK proceeds. The notes carry 10% interest and have specified default remedies and a limited guarantee, per the Form 10-Q.
  • GSK controls Utebzi commercialization in licensed territories. Spero is entitled to its 35% residual share of eligible GSK proceeds after the notes are paid in full.
  • Operating cash use of $32.1 million for the nine months was cushioned by a $25.4 million collection of a related-party receivable that is now exhausted, so 2026 is an imperfect guide to 2027 spending, per the cash flow statement.

SPRO Stock FAQ: Spero Therapeutics Questions Answered

What is Spero Therapeutics' lead program?

SP001 is an investigational antibody targeting CD40 ligand. Spero licensed it from Innovent in July 2026 and plans to study it in IgG4-related disease. The license excludes Mainland China, Hong Kong, Macau and Taiwan. See the Form 10-Q.

What is the status of Utebzi?

The FDA approval notice covers complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms in adults with limited or no alternative oral treatment options. GSK owns the NDA and controls commercialization in licensed territories. Eligible GSK proceeds service the HCRx notes before Spero receives its residual share.

How much cash does Spero have, and how long does the company say it lasts?

Cash and cash equivalents were $107.9 million at September 30, 2026. The company states in its earnings release that cash is expected to fund operations into the second half of 2029. That is a management expectation, not a contractual commitment, and it rests on assumptions about clinical and regulatory timing.

Why was the third-quarter net loss $44.3 million?

Most of it reflects the one-time $35.0 million upfront payment to Innovent, expensed as acquired in-process research and development. Revenue was zero versus $5.4 million a year earlier, and a $3.3 million non-cash interest charge on the royalty financing appeared. Ordinary R&D was $3.2 million. See the statements of operations.

What is the HCRx royalty financing?

HCRx provided $105 million of gross financing in July 2026 without a share issuance. Eligible GSK proceeds pay principal and interest until the notes are retired, after which Spero receives 35% of GSK proceeds. The Form 10-Q describes the default provisions and limited guarantee.

Has Spero reported clinical results for SP001?

No. The company’s filings and release contain no company-reported SP001 data. Innovent completed Phase 1 studies and a Phase 1b study in primary Sjögren’s disease in China, with results presented at EULAR 2026, but no numerical outcomes appear in the company’s filings or release. Spero plans a Phase 2 in IgG4-related disease, subject to IND clearance, per the earnings release.

Has shareholder dilution occurred?

Restricted stock unit vesting added 1,822,420 shares over nine months, bringing shares outstanding to 58,237,077 at September 30, 2026. Spero had 58,264,577 shares outstanding on November 6. The increase in authorized shares to 240 million and the $100 million Jefferies ATM provide capacity for future issuance. See the Form 10-Q.

What leadership changes has Spero disclosed?

The Chief Operating Officer announced retirement effective December 31, 2026, with consulting through about February 28, 2027, per the Form 8-K filed October 27, 2026. A Class II director change took effect November 10, 2026, per the Form 8-K. A new Chief Medical Officer (appointed July 2026) and a Chief Regulatory and Quality Officer were also added, per the earnings release.

Sources and scientific literature

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SPRO or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biopharmaceutical companies face clinical, regulatory, manufacturing, reimbursement, commercialization and financing risks, including dilution. Results from development programs may not translate into approval or commercial performance. Investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.